{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:54:50Z","timestamp":1793886890366,"version":"4.8.0"},"reference-count":39,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2021YFA1101803"],"award-info":[{"award-number":["2021YFA1101803"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870912"],"award-info":[{"award-number":["81870912"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82090042"],"award-info":[{"award-number":["82090042"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171293"],"award-info":[{"award-number":["82171293"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Stroke Vasc Neurol"],"accepted":{"date-parts":[[2023,3,23]]},"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Poststroke depression and anxiety, independent predictor of poor functional outcomes, are common in the acute phase of stroke. Up to now, there is no fast-onset antidepressive and anxiolytic agents suitable for the management of acute stroke. ZL006-05, a dual-target analgesic we developed, dissociates nitric oxide synthase from postsynaptic density-95 while potentiates \u03b12-containing \u03b3-aminobutyric acid type A receptor. This study aims to determine whether ZL006-05 can be used as an antistroke agent with fast-onset antidepressant and anxiolytic effects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Photothrombotic stroke and transient middle cerebral artery occlusion were induced in rats and mice. Infarct size was measured by TTC(2,3,5-Triphenyltetrazolium chloride) staining or Nissl staining. Neurological defects were assessed by four-point scale neurological score or modified Neurological Severity Scores. Grid-walking, cylinder and modified adhesive removal tasks were conducted to assess sensorimotor functions. Spatial learning was assessed using Morris water maze task. Depression and anxiety were induced by unpredictable chronic mild stress. Depressive behaviours were assessed by tail suspension, forced swim and sucrose preference tests. Anxiety behaviours were assessed by novelty-suppressed feeding and elevated plus maze tests. Pharmacokinetics, toxicokinetics and long-term toxicity studies were performed in rats.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Administration of ZL006-05 in the acute phase of stroke attenuated transient and permanent ischaemic injury and ameliorated long-term functional impairments significantly, with a treatment window of 12 hours after ischemia, and reduced plasminogen activato-induced haemorrhagic transformation. ZL006-05 produced fast-onset antidepressant and anxiolytic effects with onset latency of 1\u2009hour in the normal and CMS mice, had antidepressant and anxiolytic effects in stroke mice. ZL006-05 crossed the blood\u2013brain barrier and distributed into the brain rapidly, and had a high safety profile in toxicokinetics and long-term toxicological studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>ZL006-05 is a new neuroprotectant with fast-onset antidepressant and anxiolytic effects and has translational properties in terms of efficacy, safety and targeting of clinical issues.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/svn-2022-002156","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T11:33:31Z","timestamp":1682422411000},"page":"463-474","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":26,"title":["Preclinical evaluation of ZL006-05, a new antistroke drug with fast-onset antidepressant and anxiolytic effects"],"prefix":"10.1136","volume":"8","author":[{"given":"Haiyin","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenquan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, China"},{"name":"Department of Medicinal Chemistry, School of Pharmacy, Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Hua","sequence":"additional","affiliation":[{"name":"NeuroDawn Pharmaceutical Co., Ltd, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ren","sequence":"additional","affiliation":[{"name":"NeuroDawn Pharmaceutical Co., Ltd, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyao","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9840-0402","authenticated-orcid":false,"given":"Chunxia","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhui","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3267-0039","authenticated-orcid":false,"given":"Yilong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, School of Pharmacy, Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-0225","authenticated-orcid":false,"given":"Dongya","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,4,25]]},"reference":[{"key":"2025082410333229000_8.6.463.1","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(21)00252-0","article-title":"Global, regional, and national burden of stroke and its risk factors, 1990\u20132019: a systematic analysis for the global burden of disease study 2019","volume":"20","author":"Feigin","year":"2021","journal-title":"The Lancet Neurology"},{"key":"2025082410333229000_8.6.463.2","doi-asserted-by":"crossref","first-page":"e897","DOI":"10.1016\/S2468-2667(21)00228-0","article-title":"Temporal trend and attributable risk factors of stroke burden in China, 1990\u20132019: an analysis for the global burden of disease study 2019","volume":"6","author":"Ma","year":"2021","journal-title":"The Lancet Public Health"},{"key":"2025082410333229000_8.6.463.3","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.21100.1","article-title":"Emerging therapies in acute ischemic stroke","volume":"9","author":"Liaw","year":"2020","journal-title":"F1000Res"},{"key":"2025082410333229000_8.6.463.4","doi-asserted-by":"publisher","DOI":"10.3109\/09638288.2010.505997"},{"key":"2025082410333229000_8.6.463.5","doi-asserted-by":"crossref","first-page":"152171","DOI":"10.1016\/j.comppsych.2020.152171","article-title":"Post-Stroke depression and functional impairments-a 3-year prospective study","volume":"99","author":"Sch\u00f6ttke","year":"2020","journal-title":"Compr Psychiatry"},{"key":"2025082410333229000_8.6.463.6","doi-asserted-by":"crossref","first-page":"102636","DOI":"10.1016\/j.ajp.2021.102636","article-title":"Prevalence and predictors of new onset depression in the acute phase of stroke","volume":"59","author":"Isuru","year":"2021","journal-title":"Asian J Psychiatr"},{"key":"2025082410333229000_8.6.463.7","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2340\/16501977-2384","article-title":"Anxiety after stroke: a systematic review and meta-analysis","volume":"50","author":"Rafsten","year":"2018","journal-title":"J Rehabil Med"},{"key":"2025082410333229000_8.6.463.8","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12883-017-0980-5","article-title":"Predictors of early-onset post-ischemic stroke depression: a cross-sectional study","volume":"17","author":"Meng","year":"2017","journal-title":"BMC Neurol"},{"key":"2025082410333229000_8.6.463.9","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3389\/fpsyt.2020.00696","article-title":"Admission heart rate variability is associated with poststroke depression in patients with acute mild-moderate ischemic stroke","volume":"11","author":"He","year":"2020","journal-title":"Front Psychiatry"},{"key":"2025082410333229000_8.6.463.10","doi-asserted-by":"crossref","unstructured":"Legg LA , Tilney R , Hsieh C-F , et al . n.d. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database of Systematic Reviews;2021l 11:CD009286. doi:10.1002\/14651858.CD009286.pub3","DOI":"10.1002\/14651858.CD009286.pub4"},{"key":"2025082410333229000_8.6.463.11","doi-asserted-by":"crossref","first-page":"107494","DOI":"10.1016\/j.pharmthera.2020.107494","article-title":"A hypothesis of monoamine (5-HT) -glutamate\/GABA long neural circuit: aiming for fast-onset antidepressant discovery","volume":"208","author":"Li","year":"2020","journal-title":"Pharmacol Ther"},{"key":"2025082410333229000_8.6.463.12","doi-asserted-by":"publisher","DOI":"10.1038\/nm1735"},{"key":"2025082410333229000_8.6.463.13","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2245"},{"key":"2025082410333229000_8.6.463.14","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-015-9661-9"},{"key":"2025082410333229000_8.6.463.15","doi-asserted-by":"crossref","first-page":"110142","DOI":"10.1016\/j.celrep.2021.110142","article-title":"Stepwise disassembly of GABAergic synapses during pathogenic excitotoxicity","volume":"37","author":"Garcia","year":"2021","journal-title":"Cell Rep"},{"key":"2025082410333229000_8.6.463.16","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1007\/s12035-015-9283-2","article-title":"Gephyrin cleavage in in vitro brain ischemia decreases GABAA receptor clustering and contributes to neuronal death","volume":"53","author":"Costa","year":"2016","journal-title":"Mol Neurobiol"},{"key":"2025082410333229000_8.6.463.17","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2255-20.2021"},{"key":"2025082410333229000_8.6.463.18","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.21728"},{"key":"2025082410333229000_8.6.463.19","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3502"},{"key":"2025082410333229000_8.6.463.20","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.tins.2020.10.011","article-title":"Regulation of gabaars by transmembrane accessory proteins","volume":"44","author":"Han","year":"2021","journal-title":"Trends in Neurosciences"},{"key":"2025082410333229000_8.6.463.21","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jamapsychiatry.2021.1559","article-title":"Effect of zuranolone vs placebo in postpartum depression: a randomized clinical trial","volume":"78","author":"Deligiannidis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"2025082410333229000_8.6.463.22","unstructured":"Edwards Z , Preuss CV . GABA receptor positive allosteric modulators. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2022."},{"key":"2025082410333229000_8.6.463.23","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1038\/ncomms7803","article-title":"Analgesia and unwanted benzodiazepine effects in point-mutated mice expressing only one benzodiazepine-sensitive GABAA receptor subtype","volume":"6","author":"Ralvenius","year":"2015","journal-title":"Nat Commun"},{"key":"2025082410333229000_8.6.463.24","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.7150\/thno.58364","article-title":"A pain killer without analgesic tolerance designed by co-targeting PSD-95-nnos interaction and \u03b12-containning GABAArs","volume":"11","author":"Li","year":"2021","journal-title":"Theranostics"},{"key":"2025082410333229000_8.6.463.25","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv140"},{"key":"2025082410333229000_8.6.463.26","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1161\/STROKEAHA.118.022647","article-title":"Dissociating nNOS (neuronal NO synthase) -CAPON (carboxy-terminal postsynaptic density-95\/discs large\/zona occludens-1 ligand of nNOS) interaction promotes functional recovery after stroke via enhanced structural neuroplasticity","volume":"50","author":"Ni","year":"2019","journal-title":"Stroke"},{"key":"2025082410333229000_8.6.463.27","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s12975-022-00992-y","article-title":"Compartmentalized actions of the plasminogen activator inhibitors, PAI-1 and NSP, in ischemic stroke","volume":"13","author":"Torrente","year":"2022","journal-title":"Transl Stroke Res"},{"key":"2025082410333229000_8.6.463.28","doi-asserted-by":"publisher","DOI":"10.1161\/hs1101.098367"},{"key":"2025082410333229000_8.6.463.29","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0341-17.2017"},{"key":"2025082410333229000_8.6.463.30","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2007.359"},{"key":"2025082410333229000_8.6.463.31","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0004-11.2011"},{"key":"2025082410333229000_8.6.463.32","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-018-0011-z"},{"key":"2025082410333229000_8.6.463.33","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.5880-09.2010"},{"key":"2025082410333229000_8.6.463.34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16198-5"},{"key":"2025082410333229000_8.6.463.35","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1305-14.2014"},{"key":"2025082410333229000_8.6.463.36","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1161\/STROKEAHA.120.031197","article-title":"Edaravone dexborneol versus edaravone alone for the treatment of acute ischemic stroke: a phase III, randomized, double-blind, comparative trial","volume":"52","author":"Xu","year":"2021","journal-title":"Stroke"},{"key":"2025082410333229000_8.6.463.37","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2013.57"},{"key":"2025082410333229000_8.6.463.38","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3644"},{"key":"2025082410333229000_8.6.463.39","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0531-14.2014"}],"container-title":["Stroke and Vascular Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/svn-2022-002156","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T17:33:48Z","timestamp":1756056828000},"score":1,"resource":{"primary":{"URL":"https:\/\/svn.bmj.com\/lookup\/doi\/10.1136\/svn-2022-002156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,12,29]]},"published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1136\/svn-2022-002156"],"URL":"https:\/\/doi.org\/10.1136\/svn-2022-002156","relation":{},"ISSN":["2059-8688","2059-8696"],"issn-type":[{"value":"2059-8688","type":"print"},{"value":"2059-8696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,25]]}}}